In all, we selected 4 of the 11 groups (each treatment started at one day after cerebral ischemia) for this study: 1) a low-dose combination of EPO (2500 U/kg) + G-CSF (50 μg/kg) (Group I), 2) G-CSF alone (50 μg/kg) (Group C), 3) EPO alone (5000 U/kg) (Group D), and 4) a saline control (Fig. 4B). The gene discussed is CSF3; the disease is brain ischemia.